(CLB) Core Laboratories - Overview
Sector: Energy | Industry: Oil & Gas Equipment & Services | Exchange: NYSE (USA) | Market Cap: 795m USD | Total Return: 37.7% in 12m
Reservoir Analysis, Production Services, Laboratory Testing, Data Services
Total Rating 56
Safety 80
Buy Signal 0.05
Oil & Gas Equipment & Services
Industry Rotation: -19.3
Industry Rotation: -19.3
Market Cap:
795M
Avg Turnover: 6.07M USD
Avg Turnover: 6.07M USD
ATR:
4.57%
Peers RS (IBD): 11.0
Peers RS (IBD): 11.0
Risk 5d forecast
Volatility50.7%
Rel. Tail Risk-5.40%
Reward TTM
Sharpe Ratio0.74
Alpha-5.66
Character TTM
Beta1.303
Beta Downside1.805
Drawdowns 3y
Max DD64.29%
CAGR/Max DD-0.14
EPS (Earnings per Share)
EPS CAGR: 29.35%
EPS Trend: 53.1%
EPS Trend: 53.1%
Last SUE: 1.16
Qual. Beats: 2
Qual. Beats: 2
Revenue
Rev. CAGR: 4.96%
Rev. Trend: 74.9%
Rev. Trend: 74.9%
Last SUE: 2.77
Qual. Beats: 2
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: CLB Core Laboratories
Core Laboratories NV (CLB) provides services and products to the oil and gas industry, operating through two segments: Reservoir Description and Production Enhancement.
The Reservoir Description segment focuses on analyzing reservoir rock and fluid samples to optimize oil and gas recovery. This segment is critical for upstream oil and gas companies, as understanding reservoir characteristics directly impacts extraction efficiency. It also supports emerging areas such as carbon capture and geothermal projects, reflecting a diversification within the energy sector.
The Production Enhancement segment offers services and products for well completions, perforations, stimulations, production, and abandonment. These services are essential for maximizing output from existing wells and managing their lifecycle. The company employs a direct sales force, seminars, and trade shows for marketing.
For more detailed financial and operational insights, consider exploring ValueRay.
- Global oil and gas exploration spending dictates reservoir description demand
- Oilfield services activity drives production enhancement revenue
- Crude oil price volatility impacts client investment decisions
- Regulatory changes in carbon capture affect new service opportunities
Piotroski VR‑10 (Strict)
6.5
| Net Income: 31.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.50 > 1.0 |
| NWC/Revenue: 21.88% < 20% (prev 24.63%; Δ -2.75% < -1%) |
| CFO/TA 0.06 > 3% & CFO 37.8m > Net Income 31.8m |
| Net Debt (183.5m) to EBITDA (73.4m): 2.50 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.5m) vs 12m ago -2.66% < -2% |
| Gross Margin: 17.91% > 18% (prev 0.17%; Δ 1.77k% > 0.5%) |
| Asset Turnover: 88.69% > 50% (prev 88.73%; Δ -0.04% > 0%) |
| Interest Coverage Ratio: 5.58 > 6 (EBITDA TTM 73.4m / Interest Expense TTM 9.86m) |
Altman Z''
4.33
| A: 0.19 (Total Current Assets 222.4m - Total Current Liabilities 107.2m) / Total Assets 597.0m |
| B: 0.29 (Retained Earnings 172.7m / Total Assets 597.0m) |
| C: 0.09 (EBIT TTM 55.0m / Avg Total Assets 593.7m) |
| D: 1.43 (Book Value of Equity 452.4m / Total Liabilities 317.2m) |
| Altman-Z'' Score: 4.33 = AA |
Beneish M
-3.19
| DSRI: 0.89 (Receivables 113.5m/127.4m, Revenue 526.5m/523.8m) |
| GMI: 0.94 (GM 17.91% / 16.87%) |
| AQI: 0.98 (AQ_t 0.35 / AQ_t-1 0.36) |
| SGI: 1.01 (Revenue 526.5m / 523.8m) |
| TATA: -0.01 (NI 31.8m - CFO 37.8m) / TA 597.0m) |
| Beneish M-Score: -3.19 (Cap -4..+1) = AA |
What is the price of CLB shares?
As of April 16, 2026, the stock is trading at USD 16.46 with a total of 183,273 shares traded.
Over the past week, the price has changed by -1.79%, over one month by +4.38%, over three months by -16.06% and over the past year by +37.69%.
Over the past week, the price has changed by -1.79%, over one month by +4.38%, over three months by -16.06% and over the past year by +37.69%.
Is CLB a buy, sell or hold?
Core Laboratories has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CLB price?
| Analysts Target Price | 16.2 | -1.8% |
Core Laboratories (CLB) - Fundamental Data Overview
as of 15 April 2026
P/E Trailing = 27.0952 P/E Forward = 19.7628
P/S = 1.5096
P/B = 2.9552
P/EG = 1.6717
Revenue TTM = 526.5m USD
EBIT TTM = 55.0m USD
EBITDA TTM = 73.4m USD
Long Term Debt = 110.3m USD (from longTermDebt, last quarter)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 206.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 183.5m USD (from netDebt column, last quarter)
Enterprise Value = 978.3m USD (794.8m + Debt 206.3m - CCE 22.8m)
Interest Coverage Ratio = 5.58 (Ebit TTM 55.0m / Interest Expense TTM 9.86m)
EV/FCF = 42.63x (Enterprise Value 978.3m / FCF TTM 22.9m)
FCF Yield = 2.35% (FCF TTM 22.9m / Enterprise Value 978.3m)
FCF Margin = 4.36% (FCF TTM 22.9m / Revenue TTM 526.5m)
Net Margin = 6.04% (Net Income TTM 31.8m / Revenue TTM 526.5m)
Gross Margin = 17.91% ((Revenue TTM 526.5m - Cost of Revenue TTM 432.2m) / Revenue TTM)
Gross Margin QoQ = 18.13% (prev 19.35%)
Tobins Q-Ratio = 1.64 (Enterprise Value 978.3m / Total Assets 597.0m)
Interest Expense / Debt = 0.92% (Interest Expense 1.90m / Debt 206.3m)
Taxrate = 45.07% (5.96m / 13.2m)
NOPAT = 30.2m (EBIT 55.0m * (1 - 45.07%))
Current Ratio = 2.07 (Total Current Assets 222.4m / Total Current Liabilities 107.2m)
Debt / Equity = 0.74 (Debt 206.3m / totalStockholderEquity, last quarter 279.8m)
Debt / EBITDA = 2.50 (Net Debt 183.5m / EBITDA 73.4m)
Debt / FCF = 8.00 (Net Debt 183.5m / FCF TTM 22.9m)
Total Stockholder Equity = 266.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.36% (Net Income 31.8m / Total Assets 597.0m)
RoE = 11.94% (Net Income TTM 31.8m / Total Stockholder Equity 266.4m)
RoCE = 14.60% (EBIT 55.0m / Capital Employed (Equity 266.4m + L.T.Debt 110.3m))
RoIC = 7.92% (NOPAT 30.2m / Invested Capital 381.3m)
WACC = 8.53% (E(794.8m)/V(1.00b) * Re(10.61%) + D(206.3m)/V(1.00b) * Rd(0.92%) * (1-Tc(0.45)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.12%
[DCF] Terminal Value 79.89% ; FCFF base≈31.1m ; Y1≈38.4m ; Y5≈65.5m
[DCF] Fair Price = 18.05 (EV 1.01b - Net Debt 183.5m = Equity 831.0m / Shares 46.0m; r=8.53% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 53.14 | EPS CAGR: 29.35% | SUE: 1.16 | # QB: 2
Revenue Correlation: 74.92 | Revenue CAGR: 4.96% | SUE: 2.77 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.20 | Chg7d=+0.010 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.80 | Chg7d=+0.048 | Chg30d=+0.048 | Revisions Net=+1 | Growth EPS=+6.0% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=0.90 | Chg7d=+0.900 | Chg30d=+0.900 | Revisions Net=-1 | Growth EPS=+13.2% | Growth Revenue=+3.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.9% (Discount Rate 10.6% - Earnings Yield 3.7%)
[Growth] Growth Spread = -5.7% (Analyst 1.2% - Implied 6.9%)
External Resources